Leena Gandhi
Director/Board Member at NEXIMMUNE, INC.
Profile
Dr. Leena Gandhi is a Chief Medical Officer at Nextpoint Therapeutics, Inc. and an Independent Non-Executive Director at NexImmune, Inc. She is on the Board of Directors at NexImmune, Inc. and Bright Peak Therapeutics, Inc. Dr. Gandhi was previously employed as a Director-Cancer Therapeutic Innovation by Dana-Farber Cancer Institute, Inc., a Vice President-Immuno Oncology Development by Eli Lilly & Co., and a Director-Thoracic Medical Oncology by New York University.
She received her undergraduate degree from the University of Utah, a graduate degree from New York University and a doctorate degree from the University of California, Berkeley.
Leena Gandhi active positions
| Companies | Position | Start |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 2022-04-30 |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Director/Board Member | 2022-02-27 |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Chief Tech/Sci/R&D Officer | 2022-12-31 |
Former positions of Leena Gandhi
| Companies | Position | End |
|---|---|---|
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2022-12-31 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 2020-04-30 |
| New York University | Corporate Officer/Principal | 2018-05-31 |
Training of Leena Gandhi
| University of Utah | Undergraduate Degree |
| New York University | Graduate Degree |
| University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| NEXIMMUNE, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Commercial Services |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Health Technology |
- Stock Market
- Insiders
- Leena Gandhi
